Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $12.29 USD
Change Today +1.12 / 10.03%
Volume 462.6K
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

201 Elliott Avenue West

Seattle, WA 98119

United States

Phone: 206-676-5000

Fax: 206-676-5005

The company is evaluating alternative approaches to make OMS201 commercially available, such as through a registered outsourcing facility without the need to conduct any additional clinical trials. Preclinical Programs Phosphodiesterase 7 (PDE7) Program - OMS527 The company’s PDE7 program is based on its discoveries of previously unknown links between PDE7 and any addiction or compulsive disorder and between PDE7 and any movement disorders, such as Parkinson’s disease. PDE7 appears to modulate the dopaminergic system, which plays a significant role in regulating both addiction and movement. Exclusive License Agreement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo): The company holds an exclusive license to certain PDE7 inhibitors claimed in patents and pending patent applications owned by Daiichi Sankyo, for use in the treatment of movement, addiction, and compulsive disorders, as well as other specified indications. Plasmin Program - OMS616 The company is developing antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma or other hyperfibrinolytic conditions. The company’s proprietary agents also inhibit plasmin but, unlike Trasylol, they do not significantly inhibit kallikrein or Factor XIa. Additionally, the company’s agents are derived from human protein, which may reduce immunological side effects. MASP Program - OMS906 The company has expanded its intellectual property position to protect inventions stemming from discoveries that are directed to inhibition of both the lectin and/or alternative pathway, and it is developing inhibitors of the alternative pathway, as well as inhibitors of both the alternative and lectin pathways. The company has identified MASP-3 as the primary activator of the alternative pathway and are developing MASP-3 inhibitors that show the potential to treat subjects suffering from a range of diseases and conditions, including paroxysmal nocturnal hemoglobinuria age-related macular degeneration, ischemia-reperfusion injury, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet’s disease. Licensing Arrangements: The company jointly owns and holds worldwide exclusive license rights related to therapeutic applications for inhibiting MASP-3 from the University of Leicester. GPR17 Program The company is optimizing compounds against GPR17, a G protein-coupled receptor (GPCR) that is linked to myelin formation. Antibody Platform The company’s proprietary ex vivo platform for the discovery of novel, high-affinity monoclonal antibodies, which was in-licensed from the University of Washington and then further developed by its scientists, utilizes a chicken B-cell lymphoma cell line and has demonstrated potential for the generation of diverse antibodies that can be readily engineered. Agreements The company uses third parties to produce, store and distribute Omidria. The company has agreements with Patheon Manufacturing Services, LLC, and with Hospira Worldwide, Inc., or Hospira, and Hospira S.p.A., for commercial supply of Omidria. The company has an exclusive license agreement with Helion Biotech ApS, or Helion, pursuant to which it received a royalty-bearing, worldwide exclusive license to all of Helion’s intellectual property rights related to MASP-2 antibodies, polypeptides and methods in the field of inhibition of mannan-binding lectin-mediated activation of the complement system for the prevention, treatment or diagnosis of any disease or condition. Sales and Marketing The company has retained all worldwide marketing and distribution rights to Omidria, its product candidates and its programs, which provides it the opportunity to market and sell Omidria or any of its product candidates, if approved, independently, to make arrangements with third parties to perform these services for it, or both. With respect to Omidria, the company has developed its own internal marketing and sales management capabilities and in the U.S. are utilizing a co


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $12.29 USD +1.12

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies

Industry Analysis


Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 117.2x
Price/Book 58.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 96.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at